NCT02645864View on ClinicalTrials.gov

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Apatinib

250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)

DRUG

Irinotecan

150mg/m\^2 i.v. q2w

Trial Locations (1)

100142

Peking University Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Peking University

OTHER

NCT02645864 - Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter